Compare BioNTech SE - ADR (BNTX) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Quanta Services Inc — how do they compare? BioNTech SE - ADR trades at $90.35 (market cap $22.86B), while Quanta Services Inc trades at $638.68 (market cap $99.18B). The key difference: Quanta Services Inc is far larger — about 4.3× BioNTech SE - ADR's market cap, and Quanta Services Inc pays a 0.07% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | PWR | |
|---|---|---|
Market Cap | $22.86B | $99.18B |
Sector | Health | Industrials |
52-Week High | $119.34 | $785.24 |
52-Week Low | $83.89 | $372.50 |
Enterprise Value | $6.53B | $105.14B |
Dividend Yield | — | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Quanta Services (PWR) trades at $646.70, down 1.8% with a bearish technical signal despite strong fundamentals. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Revenue growth remains robust, climbing from $17.1B in 2022 to $28.5B in 2025, though net margins are thin at 3.67%. Analyst consensus is strongly bullish with a $836.80 price target, representing 29% upside potential from current levels.
PWR offers exposure to infrastructure spending tailwinds from AI data centers and grid modernization, but faces valuation concerns with a P/E of 88.7. The stock's premium multiple requires flawless execution amid aggressive capital expenditure plans. Near-term technical weakness contrasts with strong institutional support and positive earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
